Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for OptimizeRx (OPRX) over the last 13 years, with Q3 2025 value amounting to $91000.0.

  • OptimizeRx's Interest & Investment Income fell 1495.33% to $91000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $367000.0, marking a year-over-year increase of 455.84%. This contributed to the annual value of $329000.0 for FY2024, which is 8499.09% down from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's Interest & Investment Income is $91000.0, which was down 1495.33% from $90000.0 recorded in Q2 2025.
  • OptimizeRx's Interest & Investment Income's 5-year high stood at $721000.0 during Q2 2023, with a 5-year trough of $931.0 in Q1 2021.
  • Over the past 4 years, OptimizeRx's median Interest & Investment Income value was $91000.0 (recorded in 2025), while the average stood at $187265.2.
  • As far as peak fluctuations go, OptimizeRx's Interest & Investment Income crashed by 9831.71% in 2021, and later soared by 34000.0% in 2025.
  • Quarter analysis of 4 years shows OptimizeRx's Interest & Investment Income stood at $2382.0 in 2021, then skyrocketed by 4853.82% to $118000.0 in 2023, then dropped by 16.95% to $98000.0 in 2024, then fell by 7.14% to $91000.0 in 2025.
  • Its Interest & Investment Income was $91000.0 in Q3 2025, compared to $90000.0 in Q2 2025 and $88000.0 in Q1 2025.